Seo Young Sohn, Yun Jin Kim, Sungsoo Cho, Sung Woo Cho
{"title":"胺碘酮诱导甲状腺功能障碍的发生率和危险因素:一项全国回顾性队列研究。","authors":"Seo Young Sohn, Yun Jin Kim, Sungsoo Cho, Sung Woo Cho","doi":"10.1007/s40256-024-00717-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.</p><p><strong>Methods: </strong>This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database. A Cox regression analysis was performed to determine independent risk factors for amiodarone-induced thyroid dysfunction.</p><p><strong>Results: </strong>During a mean follow-up period of 6.4 years, 1326 (4.9%) patients developed thyrotoxicosis and 3121 (11.5%) developed hypothyroidism. The incidence rate of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) was 6.92 and 17.1 per 1000 person-years, respectively. In the multivariate analysis, chronic kidney disease (CKD) [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.06-1.99], and Hashimoto's thyroiditis (HR 2.00, 95% CI 1.31-3.07) were associated with AIT, while female sex (HR 1.22, 95% CI 1.14-1.32), diabetes (HR 1.14, 95% CI 1.06-1.24), CKD (HR 1.18, 95% CI 1.05-1.34), and Hashimoto's thyroiditis (HR 2.26, 95% CI 1.66-3.09) were associated with AIH.</p><p><strong>Conclusions: </strong>The incidence of AIH was higher compared with AIT in an area with sufficient iodine intake. Several potential risk factors for AIT and AIH were identified. When amiodarone treatment is considered for patients, particularly those at a high risk of thyroid dysfunction, it is warranted to perform regular thyroid function assessments.</p>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study.\",\"authors\":\"Seo Young Sohn, Yun Jin Kim, Sungsoo Cho, Sung Woo Cho\",\"doi\":\"10.1007/s40256-024-00717-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.</p><p><strong>Methods: </strong>This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database. A Cox regression analysis was performed to determine independent risk factors for amiodarone-induced thyroid dysfunction.</p><p><strong>Results: </strong>During a mean follow-up period of 6.4 years, 1326 (4.9%) patients developed thyrotoxicosis and 3121 (11.5%) developed hypothyroidism. The incidence rate of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) was 6.92 and 17.1 per 1000 person-years, respectively. In the multivariate analysis, chronic kidney disease (CKD) [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.06-1.99], and Hashimoto's thyroiditis (HR 2.00, 95% CI 1.31-3.07) were associated with AIT, while female sex (HR 1.22, 95% CI 1.14-1.32), diabetes (HR 1.14, 95% CI 1.06-1.24), CKD (HR 1.18, 95% CI 1.05-1.34), and Hashimoto's thyroiditis (HR 2.26, 95% CI 1.66-3.09) were associated with AIH.</p><p><strong>Conclusions: </strong>The incidence of AIH was higher compared with AIT in an area with sufficient iodine intake. Several potential risk factors for AIT and AIH were identified. When amiodarone treatment is considered for patients, particularly those at a high risk of thyroid dysfunction, it is warranted to perform regular thyroid function assessments.</p>\",\"PeriodicalId\":7652,\"journal\":{\"name\":\"American Journal of Cardiovascular Drugs\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Cardiovascular Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40256-024-00717-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiovascular Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40256-024-00717-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:胺碘酮是一种有效的抗心律失常药物;然而,它经常与甲状腺功能障碍有关。本研究的目的是调查胺碘酮在碘充足地区诱发功能障碍的发生率和危险因素。方法:本回顾性队列研究纳入27,023例连续使用胺碘酮治疗心律失常的患者,使用韩国国民健康保险数据库。采用Cox回归分析确定胺碘酮诱导甲状腺功能障碍的独立危险因素。结果:在平均6.4年的随访期间,1326例(4.9%)患者发生甲状腺毒症,3121例(11.5%)患者发生甲状腺功能减退。胺碘酮致甲状腺毒症(AIT)和胺碘酮致甲状腺功能减退症(AIH)的发病率分别为6.92和17.1 / 1000人年。在多因素分析中,慢性肾脏疾病(CKD)[危险比(HR) 1.46, 95%可信区间(CI) 1.06-1.99]和桥本氏甲状腺炎(HR 2.00, 95% CI 1.31-3.07)与AIH相关,而女性(HR 1.22, 95% CI 1.14-1.32)、糖尿病(HR 1.14, 95% CI 1.06-1.24)、CKD (HR 1.18, 95% CI 1.05-1.34)和桥本氏甲状腺炎(HR 2.26, 95% CI 1.66-3.09)与AIH相关。结论:在碘摄入充足的地区,AIH的发生率高于AIT。确定了aiit和AIH的几个潜在危险因素。当考虑对患者进行胺碘酮治疗时,特别是那些甲状腺功能障碍高风险的患者,有必要定期进行甲状腺功能评估。
Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study.
Background: Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.
Methods: This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database. A Cox regression analysis was performed to determine independent risk factors for amiodarone-induced thyroid dysfunction.
Results: During a mean follow-up period of 6.4 years, 1326 (4.9%) patients developed thyrotoxicosis and 3121 (11.5%) developed hypothyroidism. The incidence rate of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) was 6.92 and 17.1 per 1000 person-years, respectively. In the multivariate analysis, chronic kidney disease (CKD) [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.06-1.99], and Hashimoto's thyroiditis (HR 2.00, 95% CI 1.31-3.07) were associated with AIT, while female sex (HR 1.22, 95% CI 1.14-1.32), diabetes (HR 1.14, 95% CI 1.06-1.24), CKD (HR 1.18, 95% CI 1.05-1.34), and Hashimoto's thyroiditis (HR 2.26, 95% CI 1.66-3.09) were associated with AIH.
Conclusions: The incidence of AIH was higher compared with AIT in an area with sufficient iodine intake. Several potential risk factors for AIT and AIH were identified. When amiodarone treatment is considered for patients, particularly those at a high risk of thyroid dysfunction, it is warranted to perform regular thyroid function assessments.
期刊介绍:
Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.
Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.
The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.